NEW YORK (Reuters Health) – Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, significantly improved overall survival versus sorafenib in first-line treatment of
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
